Literature DB >> 30128739

IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells.

Julian Plaumann1, Melanie Engelhardt1, Mohamed H S Awwad1, Hakim Echchannaoui2, Eva Amman2, Marc S Raab1, Jens Hillengass1, Niels Halama3, Brigitte Neuber1, Carsten Müller-Tidow1, Hartmut Goldschmidt1,3, Michael Hundemer4.   

Abstract

Tumor-mediated immunosuppression via regulatory T-cells is a key player among the various immune-escape mechanisms in multiple myeloma. We analyzed the generation, distribution, function and immunophenotype of CD8+CD28- regulatory T-cells in patients with multiple myeloma. Functionality of CD8+CD28- T-cells was assessed by immunological assays using ex vivo generated antigen-specific T-cells from patients with plasma cell dyscrasias and healthy donors. Detailed analysis of distribution, immunophenotype and cytotoxic potential of CD8+CD28- T-cells was performed by flow cytometry and ELISA. We found that the amount of CD8+CD28- T-cells was directly correlated with the suppression of antigen-specific T-cell responses in patients with plasma cell dyscrasia. Analyzing the CD8+CD28- T-cells in detail, increased numbers of these cells were observed in the bone marrow (i.e., tumor microenvironment) of patients with plasma cell dyscrasia. Furthermore, we identified the expression of lymphocyte function-associated antigen 1 (LFA-1) as a marker of immunosuppression and defined the CD8+CD28-CD57+LFA-1high population as the relevant immunosuppressive compartment. These regulatory T-cells act as immunosuppressors via soluble factors and incubation with IL-10 augmented their immunosuppressive capacity. The immunosuppressive regulatory network of IL-10 and the CD8+CD28-CD57+LFA-1high regulatory T-cells show unique characteristics and contribute to the tumor immune escape mechanism in patients with multiple myeloma.

Entities:  

Keywords:  CD57+; IL-10; LFA-1; Multiple myeloma

Mesh:

Substances:

Year:  2018        PMID: 30128739     DOI: 10.1007/s00262-018-2230-0

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

1.  T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.

Authors:  Fabienne Lucas; Michael Pennell; Ying Huang; Don M Benson; Yvonne A Efebera; Maria Chaudhry; Tiffany Hughes; Jennifer A Woyach; John C Byrd; Suohui Zhang; Desiree Jones; Xiangnan Guan; Christin E Burd; Ashley E Rosko
Journal:  Biol Blood Marrow Transplant       Date:  2019-08-21       Impact factor: 5.742

2.  Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma.

Authors:  Binod Dhakal; Adam Pagenkopf; Muhammad Umair Mushtaq; Ashley M Cunningham; Evan Flietner; Zachary Morrow; Athanasios Papadas; Chelsea Hope; Catherine Leith; Peiman Hematti; Parameswaran Hari; Natalie S Callander; Fotis Asimakopoulos
Journal:  Leuk Lymphoma       Date:  2019-03-08

Review 3.  CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies.

Authors:  Jian-Qing Mi; Jie Xu; Jianfeng Zhou; Weili Zhao; Zhu Chen; J Joseph Melenhorst; Saijuan Chen
Journal:  Front Med       Date:  2021-12-18       Impact factor: 4.592

Review 4.  The Evolving Role of CD8+CD28- Immunosenescent T Cells in Cancer Immunology.

Authors:  Wei X Huff; Jae Hyun Kwon; Mario Henriquez; Kaleigh Fetcko; Mahua Dey
Journal:  Int J Mol Sci       Date:  2019-06-08       Impact factor: 5.923

5.  Effect of early restrictive fluid resuscitation on inflammatory and immune factors in patients with severe pelvic fracture.

Authors:  La-Mei Jiang; Jun He; Xiao-Yan Xi; Chun-Mei Huang
Journal:  Chin J Traumatol       Date:  2019-09-20

Review 6.  Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy.

Authors:  Bhalchandra Mirlekar
Journal:  SAGE Open Med       Date:  2022-01-25

7.  Selective elimination of immunosuppressive T cells in patients with multiple myeloma.

Authors:  Mohamed H S Awwad; Abdelrahman Mahmoud; Heiko Bruns; Hakim Echchannaoui; Katharina Kriegsmann; Raphael Lutz; Marc S Raab; Uta Bertsch; Markus Munder; Anna Jauch; Katja Weisel; Bettina Maier; Niels Weinhold; Hans Jürgen Salwender; Volker Eckstein; Mathias Hänel; Roland Fenk; Jan Dürig; Benedikt Brors; Axel Benner; Carsten Müller-Tidow; Hartmut Goldschmidt; Michael Hundemer
Journal:  Leukemia       Date:  2021-02-17       Impact factor: 11.528

8.  Multiple Myeloma-Derived Extracellular Vesicles Modulate the Bone Marrow Immune Microenvironment.

Authors:  Raquel Lopes; Joana Caetano; Filipa Barahona; Carolina Pestana; Bruna Velosa Ferreira; Diana Lourenço; Ana C Queirós; Carlos Bilreiro; Noam Shemesh; Hans Christian Beck; Ana Sofia Carvalho; Rune Matthiesen; Bjarne Bogen; Bruno Costa-Silva; Karine Serre; Emilie Arnault Carneiro; Cristina João
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.